Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON: Biomarker-Guided Hydrocortisone Replacement in Neurocritical Illness
KCT0012389Phase 3Not yet recruiting
- Sponsor
- Asan Medical Center
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of hydrocortisone in Relative adrenal insufficiency (CIRCI), hypoadrenocorticism, traumatic brain injury (TBI) and 3 more (2 arms), sponsored by Asan Medical Center. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
hydrocortisone
03
Conditions
Relative adrenal insufficiency (CIRCI)hypoadrenocorticismtraumatic brain injury (TBI)intracerebral hemorrhage (ICH)stroke
Beyond the preview
Go deeper on KCT0012389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012389.